Advertisement
MDT vs SYK
Which Stock Would AI Choose? Medtronic (MDT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Medtronic is showing accelerating revenue momentum, led by its cardiovascular segment and cardiac ablation products, while Stryker is recovering from an operational disruption and facing near-term moderation concerns.
- MDT offers a higher dividend yield (around 3.2%) and a lower forward valuation, while SYK historically commands a premium on stronger margins and robotics leadership.
- Stryker's Mako robotics franchise remains a key growth driver, whereas Medtronic is ramping its Hugo robotic-assisted surgery platform and a fast-growing pulsed field ablation portfolio.
- Recent market positioning favors Medtronic's improving trend, while Stryker has experienced a sharper pullback in recent weeks.
- Both carry neutral analyst ratings (Zacks Rank #3/Hold), reflecting balanced risk-reward profiles rather than clear consensus conviction.
Introduction
Medtronic and Stryker are two of the largest medical technology companies in the world, yet they compete from very different strategic positions. Medtronic is a diversified, Ireland-domiciled device maker spanning cardiovascular, neuroscience, medical-surgical, and (until recently) diabetes care. Stryker is a U.S.-based specialist in orthopaedics, MedSurg, and neurotechnology with a leading robotic-assisted surgery franchise. For investors evaluating this stock comparison, the key question is whether Medtronic's re-accelerating growth and income appeal outweigh Stryker's superior margins and robotics pipeline. This relative performance analysis is relevant to growth, value, and income-oriented investors seeking to understand how two medical-device bellwethers are positioned in the current market environment.
MDT Overview and Recent Performance
Medtronic operates across cardiovascular, neuroscience, and medical-surgical portfolios, and recently spun off its diabetes business into a separately listed entity called MiniMed. The company has reported its strongest enterprise revenue growth in roughly a decade, with fiscal-year revenue advancing in the high single digits on an organic basis. In its most recent quarter, revenue rose about 13.7% year over year, though management noted the period benefited from an extra selling week that added roughly $570 million.
Recent performance has been driven by standout growth in cardiac ablation solutions—where revenue roughly doubled—and double-digit gains in the cardiovascular portfolio. Medtronic raised its full-year organic revenue growth outlook and the lower end of its earnings guidance, signaling operational confidence. At the same time, the shares have lagged the broader market over longer horizons and remain well below their five-year highs. Sentiment has been shaped by a mix of factors, including the MiniMed separation, ongoing investment in the Hugo robotic surgery platform, and targeted acquisitions such as Scientia Vascular and SPR Therapeutics. The stock's above-average dividend yield and lower forward price-to-earnings (P/E) multiple have drawn income-focused and value-oriented attention.
SYK Overview and Recent Performance
Stryker generates revenue across three segments: MedSurg and Neurotechnology, and Orthopaedics, with a strong position in robotic-assisted joint replacement through its Mako system. The company's recent market activity has been shaped by an operational cybersecurity disruption that constrained production in one quarter, followed by a sharp recovery in the subsequent quarter, when organic sales growth rebounded to roughly 9% and adjusted earnings per share (EPS) rose nearly 18%.
Stryker's adjusted operating margin of roughly 27% remains among the strongest in the industry, supported by cost discipline and a favorable product mix. Record Mako installations and the commercial launch of Mako RPS have reinforced its robotics leadership, while acquisitions such as ZuriMED and Amplitude Vascular Systems extend its shoulder-care and vascular portfolios. Despite these strengths, the shares have pulled back noticeably in recent weeks, reflecting analyst concerns about more intense seasonality and moderating U.S. hip and knee growth in the back half of the year. The stock now trades below its five-year median valuation, a shift from the premium it has often commanded.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates a focused selection of the platform's automated trading systems. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of securities. Because only the strongest and most suitable bots for current market conditions are featured, the page offers a convenient way to filter through a broad universe of automated strategies and review their historical statistics. Whether you follow momentum, swing, or longer-horizon approaches, exploring the Trending AI Robots section can help you identify strategies that align with today's market environment.
Head-to-Head Comparison
The clearest contrast between these two companies is margin quality versus growth re-acceleration. Stryker operates with meaningfully higher adjusted operating margins and a focused, high-margin orthopaedics and MedSurg business model, while Medtronic runs a broader, more diversified portfolio with lower margins but an improving top-line trajectory. In terms of growth drivers, Stryker leans on Mako robotics, new product launches, and an aging-population tailwind in joint replacement; Medtronic's catalysts center on pulsed field ablation, renal denervation, and its Hugo robotic surgery ramp.
Risk factors also differ. Stryker is working through cyber-remediation costs, a peripheral vascular supply disruption, and analyst concerns about second-half procedure moderation. Medtronic faces pricing pressure in neuroscience, integration costs from its diabetes spinoff, and heavy investment to compete in surgical robotics. On sentiment, Medtronic's recent momentum has been comparatively steadier, while Stryker has experienced a sharper valuation reset. Medtronic also offers a more defensive profile through its higher dividend yield, whereas Stryker prioritizes capital deployment toward acquisitions and share repurchases.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI would likely favor MDT in the current environment. Medtronic's improving organic growth, accelerating cardiovascular momentum, raised guidance, and comparatively steadier recent price action present a more consistent trend profile, while its dividend provides an additional defensive characteristic. Stryker retains superior margins and a compelling robotics pipeline, but its sharper recent pullback and near-term execution uncertainties introduce more variability. This assessment is probabilistic rather than definitive: market conditions can shift quickly, and SYK could regain favor if its robotics-driven growth reasserts itself and seasonal concerns subside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDT is a Hold and SYK is a Buy.
MDT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 92 | |
SMR RATING 1..100 | 68 | 52 | |
PRICE GROWTH RATING 1..100 | 55 | 63 | |
P/E GROWTH RATING 1..100 | 57 | 86 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (4) in the Medical Specialties industry is in the same range as SYK (7). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (92) in the Medical Specialties industry is in the same range as MDT (100). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
SYK's SMR Rating (52) in the Medical Specialties industry is in the same range as MDT (68). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (55) in the Medical Specialties industry is in the same range as SYK (63). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
MDT's P/E Growth Rating (57) in the Medical Specialties industry is in the same range as SYK (86). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
| MDT | SYK | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 79% |
| Stochastic ODDS (%) | 3 days ago 48% | 3 days ago 59% |
| Momentum ODDS (%) | 3 days ago 54% | 3 days ago 61% |
| MACD ODDS (%) | 7 days ago 45% | 3 days ago 74% |
| TrendWeek ODDS (%) | 3 days ago 54% | 3 days ago 55% |
| TrendMonth ODDS (%) | 3 days ago 52% | 3 days ago 53% |
| Advances ODDS (%) | 7 days ago 54% | 6 days ago 57% |
| Declines ODDS (%) | 5 days ago 55% | 4 days ago 51% |
| BollingerBands ODDS (%) | 3 days ago 58% | 3 days ago 73% |
| Aroon ODDS (%) | 3 days ago 43% | 3 days ago 47% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green while SYK’s FA Score has 1 green FA rating(s).
- MDT’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 6 bullish TA indicator(s).
- MDT’s TA Score: 4 bullish, 6 bearish.
- SYK’s TA Score: 6 bullish, 4 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а -2.55% price change this week, while SYK (@Medical/Nursing Services) price change was +1.45% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.13%. For the same industry, the average monthly price growth was -5.92%, and the average quarterly price growth was -2.70%.
Reported Earning Dates
MDT is expected to report earnings on Nov 24, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.13% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.